Liquid formulation
The invention relates to a liquid formulation comprising propylene glycol and an effective amount of an inodilator, an angiotensin converting enzyme inhibitor, or a combination of an inodilator and an angiotensin converting enzyme inhibitor and to use of the formulation for treating cardiac disease and/or hypertension.
1. An orally bioavailable liquid formulation comprising 7 wt % to about 65 wt % of the total formulation of propylene glycol and a combination of an inodilator selected from the group consisting of pimobendan, a pharmaceutically acceptable salt thereof, and a veterinary acceptable salt thereof, and an angiotensin converting enzyme inhibitor selected from the group consisting of enalapril, benazepril, a pharmaceutically acceptable salt thereof, and a veterinary acceptable salt thereof; wherein the inodilator and/or the angiotensin converting enzyme inhibitor is present in an amount of about 0.1 wt % to about 50 wt % of the total formulation.
2. A liquid formulation comprising 7 wt % to about 65 wt % of the total formulation of propylene glycol and an effective amount of a combination of an inodilator selected from the group consisting of pimobendan, a pharmaceutically acceptable salt thereof, and a veterinary acceptable salt thereof and an angiotensin converting enzyme inhibitor selected from the group consisting of enalapril, benazepril, a pharmaceutically acceptable salt thereof, and a veterinary acceptable salt thereof.
3. The formulation of claim 1 , further comprising one or more further active agents, wherein the one or more further active agent is a diuretic selected from the group consisting of furosemide, hydrochlorothiazide, chlorthalidone, bumetanide, ethacrynic acid, torasemide, chlorothiazide, spironolactone, triamterene, amiloride, pharmaceutically or veterinary salts thereof, and a combination thereof; wherein the further active agent is present in an amount of about 0.1 wt % to about 50 wt % of the total formulation.
4. The formulation of claim 1 , wherein the inodilator is present in an amount of about 0.1 wt % to about 50 wt % of the total formulation.
5. The formulation of claim 1 , wherein the angiotensin converting enzyme inhibitor is present in an amount of about 0.1 wt % to about 50 wt % of the total formulation.
6. A process for the preparation of the formulation of claim 1 , which comprises mixing an effective amount of the inodilator or the angiotensin converting enzyme inhibitor with propylene glycol.
7. The orally bioavailable liquid formulation of claim 1 that is non aqueous.